1. Name and Address of Reporting Person
   Zaks Tal Zvi
   C/O MODERNA, INC.
   200 TECHNOLOGY SQUARE
   CAMBRIDGE MA 02139

2. Issuer Name and Ticker or Trading Symbol
   Moderna, Inc. [ MRNA ]

3. Date of Earliest Transaction (Month/Day/Year)
   11/02/2020

4. If Amendment, Date of Original Filed (Month/Day/Year)
   11/04/2020

5. Relationship of Reporting Person(s) to Issuer
   Director
   Chief Medical Officer

6. Individual or Joint/Group Filing (Check Applicable Line)
   X Form filed by One Reporting Person
   Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

<table>
<thead>
<tr>
<th>Title of Security (Instr. 3)</th>
<th>Transaction Date (Month/Day/Year)</th>
<th>Transaction Code (Instr. 8)</th>
<th>Amount (A) or (D)</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Common Stock</td>
<td>11/02/2020</td>
<td>M(1)</td>
<td>5,000</td>
<td>$12.21</td>
</tr>
<tr>
<td>Common Stock</td>
<td>11/02/2020</td>
<td>M(1)</td>
<td>10,000</td>
<td>$19.15</td>
</tr>
<tr>
<td>Common Stock</td>
<td>11/02/2020</td>
<td>S(1)</td>
<td>13,900</td>
<td>$67.11</td>
</tr>
<tr>
<td>Common Stock</td>
<td>11/02/2020</td>
<td>S(1)</td>
<td>1,100</td>
<td>$67.88</td>
</tr>
</tbody>
</table>

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

<table>
<thead>
<tr>
<th>Title of Derivative Security (Instr. 3)</th>
<th>Conversion or Exercise Price of Derivative Security</th>
<th>Transaction Date (Month/Day/Year)</th>
<th>Transaction Code (Instr. 8)</th>
<th>Date Exercisable</th>
<th>Expiration Date</th>
<th>Title of Securities Underlying Derivative Security (Instr. 3 and 4)</th>
<th>Amount or Number of Shares</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stock Option (Right to Buy)</td>
<td>$12.21</td>
<td>11/02/2020</td>
<td>M(1)</td>
<td>5,000</td>
<td>10/03/2027</td>
<td>Common Stock</td>
<td>5,000</td>
</tr>
<tr>
<td>Stock Option (Right to Buy)</td>
<td>$19.15</td>
<td>11/02/2020</td>
<td>M(1)</td>
<td>10,000</td>
<td>08/10/2026</td>
<td>Common Stock</td>
<td>10,000</td>
</tr>
</tbody>
</table>

Explanation of Responses:

1. The reported transaction was effectuated pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020.
2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $66.58 to $67.58. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
3. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $67.60 to $68.19. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
4. 229,358 of the options will vest over 4 years (25% on the first anniversary of the grant date of October 3, 2017, then quarterly for the next 3 years). 137,614 of the options will vest over 5 years (25% on the second anniversary of the grant date of October 3, 2017, then quarterly for the next 3 years). 91,743 of the options will vest over 6 years (25% on the third anniversary of the grant date of October 3, 2017, then quarterly for the next 3 years).
5. This option is fully vested and exercisable.

/s/ Lori Henderson, as Attorney-in-Fact 11/04/2020
** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).


Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.